-
1
-
-
23844449784
-
Vitamin D treatment in chronic kidney disease
-
Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005;18:315-21.
-
(2005)
Semin Dial
, vol.18
, pp. 315-321
-
-
Andress, D.L.1
-
2
-
-
0027178439
-
The spectrum of bone disease in end-stage renal failure - An evolving disorder
-
Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993;43:436-42.
-
(1993)
Kidney Int
, vol.43
, pp. 436-442
-
-
Sherrard, D.J.1
Hercz, G.2
Pei, Y.3
-
3
-
-
23844488455
-
Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy
-
Hernandez JD, Wesseling D, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial 2005;18:290-5.
-
(2005)
Semin Dial
, vol.18
, pp. 290-295
-
-
Hernandez, J.D.1
Wesseling, D.2
Salusky, I.B.3
-
4
-
-
0031920748
-
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
-
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
-
(1998)
Am J Kidney Dis
, vol.31
, pp. 607-617
-
-
Block, G.A.1
Hulbert-Shearon, T.E.2
Levin, N.W.3
Port, F.K.4
-
6
-
-
0037138580
-
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?
-
Raggi P, Boulay A, Chasan-Taber SC, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
-
(2002)
J Am Coll Cardiol
, vol.39
, pp. 695-701
-
-
Raggi, P.1
Boulay, A.2
Chasan-Taber, S.C.3
-
7
-
-
0037850065
-
Vascular calcification in the uremic patient: A cardiovascular risk?
-
Salgueira M, Del Toro N, Moreno-Alba R, Jimenez NA, Palma A. Vascular calcification in the uremic patient: a cardiovascular risk? Kidney Int 2003;(suppl):S119-21.
-
(2003)
Kidney Int
, Issue.SUPPL.
-
-
Salgueira, M.1
Del Toro, N.2
Moreno-Alba, R.3
Jimenez, N.A.4
Palma, A.5
-
8
-
-
83055172414
-
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl):S1-203.
-
(2003)
Am J Kidney Dis
, vol.42
, Issue.SUPPL.
-
-
-
9
-
-
0036267736
-
Analysis of renal bone disease treatment in dialysis patients
-
Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 2002;39:1270-7.
-
(2002)
Am J Kidney Dis
, vol.39
, pp. 1270-1277
-
-
Johnson, C.A.1
McCarthy, J.2
Bailie, G.R.3
Deane, J.4
Smith, S.5
-
10
-
-
0033505903
-
Prevention of renal osteodystrophy in predialysis patients
-
Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci 1999;317:398-404.
-
(1999)
Am J Med Sci
, vol.317
, pp. 398-404
-
-
Sanchez, C.P.1
Goodman, W.G.2
Salusky, I.B.3
-
11
-
-
0033843456
-
Management of secondary hyperparathyroidism: The gap between diagnosis and treatment
-
Corte-Diaz C, Andia-Cannata JB. Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. Am J Med Sci 2000;320:107-11.
-
(2000)
Am J Med Sci
, vol.320
, pp. 107-111
-
-
Corte-Diaz, C.1
Andia-Cannata, J.B.2
-
12
-
-
0141526958
-
Update on renal osteodystrophy: Pathogenesis and clinical management
-
Sakhaee K, Gonzalez GB. Update on renal osteodystrophy: pathogenesis and clinical management. Am J Med Sci 1999:317:251-60.
-
(1999)
Am J Med Sci
, vol.317
, pp. 251-260
-
-
Sakhaee, K.1
Gonzalez, G.B.2
-
13
-
-
0033842408
-
Current medical management of secondary hyperparathyroidism
-
Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000;320:100-6.
-
(2000)
Am J Med Sci
, vol.320
, pp. 100-106
-
-
Yudd, M.1
Llach, F.2
-
14
-
-
0033839073
-
Adynamic bone and chronic renal failure: An overview
-
Cannata-Andia JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000;320:81-4.
-
(2000)
Am J Med Sci
, vol.320
, pp. 81-84
-
-
Cannata-Andia, J.B.1
-
15
-
-
0032892709
-
Molecular pathogenesis of secondary hyperparathyroidism in renal failure: Basic and clinical aspects
-
Fukagawa M, Iwasaki Y. Molecular pathogenesis of secondary hyperparathyroidism in renal failure: basic and clinical aspects. Nephrol Dial Transplant 1999;14(suppl):S61-2.
-
(1999)
Nephrol Dial Transplant
, vol.14
, Issue.SUPPL.
-
-
Fukagawa, M.1
Iwasaki, Y.2
-
18
-
-
0032920355
-
Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis
-
Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999;21:432-41.
-
(1999)
Clin Ther
, vol.21
, pp. 432-441
-
-
Goldenberg, M.M.1
-
19
-
-
0032954950
-
Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease
-
McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease. Kidney Int 1999;55:500-11.
-
(1999)
Kidney Int
, vol.55
, pp. 500-511
-
-
McIntyre, C.W.1
Schroeder, N.J.2
Burrin, J.M.3
Cunningham, J.4
-
21
-
-
14644392186
-
Are new vitamin D analogues in renal bone disease superior to calcitriol?
-
DOI 10.1007/s00467-004-1778-2
-
Salusky IB. Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol 2005;20:393-8. DOI 10.1007/s00467-004-1778-2
-
(2005)
Pediatr Nephrol
, vol.20
, pp. 393-398
-
-
Salusky, I.B.1
-
22
-
-
0033257480
-
Doxercalciferol
-
Doxercalciferol. Am J Health Syst Pharm 1999;56:2410-1.
-
(1999)
Am J Health Syst Pharm
, vol.56
, pp. 2410-2411
-
-
-
23
-
-
33750999268
-
-
(New Drug Application no. 20-862/S-018). Madison, WI: Bone Care International, reviewed June
-
Product information. Hectorol (doxercalciferol) (New Drug Application no. 20-862/S-018). Madison, WI: Bone Care International, reviewed June 2005.
-
(2005)
Product Information. Hectorol (Doxercalciferol)
-
-
-
24
-
-
0031769002
-
Vitamin D analogues
-
Brown AJ. Vitamin D analogues. Am J of Kidney Dis 1998;32(suppl 2):S25-39.
-
(1998)
Am J of Kidney Dis
, vol.32
, Issue.SUPPL. 2
-
-
Brown, A.J.1
-
25
-
-
0036411910
-
Vitamin D analogues for secondary hyperparathyroidism
-
Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17(suppl 10):10-9.
-
(2002)
Nephrol Dial Transplant
, vol.17
, Issue.SUPPL. 10
, pp. 10-19
-
-
Brown, A.J.1
Dusso, A.S.2
Slatopolsky, E.3
-
26
-
-
2442699046
-
Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase
-
Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004;101:7711-5.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 7711-7715
-
-
Cheng, J.B.1
Levine, M.A.2
Bell, N.H.3
Mangelsdorf, D.J.4
Russell, D.W.5
-
27
-
-
0037384889
-
Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone
-
Upton RA, Knutson JC, Bishop CW, LeVan LW. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18:750-8.
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 750-758
-
-
Upton, R.A.1
Knutson, J.C.2
Bishop, C.W.3
Levan, L.W.4
-
28
-
-
33750999268
-
-
(New Drug Application no. 21-027/S-012). Madison, WI: Bone Care International, reviewed June
-
Product information. Hectorol injection (doxercalciferol) (New Drug Application no. 21-027/S-012). Madison, WI: Bone Care International, reviewed June 2005.
-
(2005)
Product Information. Hectorol Injection (Doxercalciferol)
-
-
-
29
-
-
8044230723
-
2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
-
2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23.
-
(1997)
Kidney Int
, vol.51
, pp. 317-323
-
-
Tan Jr., A.U.1
Levine, B.S.2
Mazess, R.B.3
-
30
-
-
17144459471
-
2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison
-
DOI 10.1053/ajkd.2001.22077
-
2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-43. DOI 10.1053/ajkd.2001. 22077
-
(2001)
Am J Kidney Dis
, vol.37
, pp. 532-543
-
-
Maung, H.M.1
Elangovan, L.2
Frazao, J.M.3
-
31
-
-
1942466552
-
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
-
Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-90.
-
(2004)
Am J Kidney Dis
, vol.43
, pp. 877-890
-
-
Coburn, J.W.1
Maung, H.M.2
Elangovan, L.3
-
32
-
-
0033624518
-
2) therapy for secondary hyperparathyroidism
-
DOI 10.1053/ajkd2000.16193
-
2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;30:550-61. DOI 10.1053/ajkd2000.16193
-
(2000)
Am J Kidney Dis
, vol.30
, pp. 550-561
-
-
Frazao, J.M.1
Elangovan, L.2
Maung, H.M.3
-
33
-
-
0031637872
-
2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients
-
2 Study Group
-
2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Trans 1998;13(suppl3):S68-72.
-
(1998)
Nephrol Dial Trans
, vol.13
, Issue.SUPPL. 3
-
-
Frazao, J.M.1
Chesney, R.W.2
Coburn, J.W.3
-
34
-
-
0026785324
-
Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients
-
Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992;42:1191-8.
-
(1992)
Kidney Int
, vol.42
, pp. 1191-1198
-
-
Gallieni, M.1
Brancaccio, D.2
Padovese, P.3
-
35
-
-
0034049012
-
Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
-
Indridason OS, Quarles D. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000;57:282-92.
-
(2000)
Kidney Int
, vol.57
, pp. 282-292
-
-
Indridason, O.S.1
Quarles, D.2
-
37
-
-
0037378444
-
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
-
Sprague SM, Llach F, Amdahl M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90.
-
(2003)
Kidney Int
, vol.63
, pp. 1483-1490
-
-
Sprague, S.M.1
Llach, F.2
Amdahl, M.3
Taccetta, C.4
Battle, D.5
-
38
-
-
29144522280
-
Inhibition of parathyroid hormone: A dose equivalency study of paricalcitol and doxercalciferol
-
DOI 10.1159/000089707
-
Zisman AL, Ghantous W, Schinleber P, Roberts L. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 2005;25:591-5. DOI 10.1159/000089707
-
(2005)
Am J Nephrol
, vol.25
, pp. 591-595
-
-
Zisman, A.L.1
Ghantous, W.2
Schinleber, P.3
Roberts, L.4
-
39
-
-
0036023018
-
Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient
-
Sprague SM, Ho LT. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol 2002;58:1555-60.
-
(2002)
Clin Nephrol
, vol.58
, pp. 1555-1560
-
-
Sprague, S.M.1
Ho, L.T.2
-
40
-
-
0038715733
-
2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy
-
2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy. Clin Nephrol 2003;59:471-4.
-
(2003)
Clin Nephrol
, vol.59
, pp. 471-474
-
-
Parisi, M.S.1
Oliveri, B.2
Somoza, J.3
Mautalen, C.4
-
45
-
-
0037512524
-
Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4
-
Coburn JW, Maung HM. Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney Int 2003;63(suppl 85): S49-53.
-
(2003)
Kidney Int
, vol.63
, Issue.SUPPL. 85
-
-
Coburn, J.W.1
Maung, H.M.2
-
46
-
-
33750968410
-
K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease
-
(accessed 2005 Aug 10)
-
K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation DOQI Guidelines. www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm (accessed 2005 Aug 10).
-
National Kidney Foundation DOQI Guidelines
-
-
-
48
-
-
0032944582
-
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
-
Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
-
(1999)
Am J Kidney Dis
, vol.33
, pp. 694-701
-
-
Bleyer, A.J.1
Burke, S.K.2
Dillon, M.3
-
49
-
-
0036310682
-
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
-
Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
-
(2002)
Kidney Int
, vol.62
, pp. 245-252
-
-
Chertow, G.M.1
Burke, S.K.2
Raggi, P.3
-
50
-
-
0038386468
-
Randomized, double-blind, placebo-controlled dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia
-
Joy MS, Finn W. Randomized, double-blind, placebo-controlled dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 96-107
-
-
Joy, M.S.1
Finn, W.2
-
51
-
-
21044458627
-
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease
-
Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-70.
-
(2005)
Clin Nephrol
, vol.63
, pp. 461-470
-
-
Chiang, S.S.1
Chen, J.B.2
Yang, W.C.3
-
52
-
-
0038187803
-
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients
-
D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63(suppl 85):S73-8.
-
(2003)
Kidney Int
, vol.63
, Issue.SUPPL. 85
-
-
D'Haese, P.C.1
Spasovski, G.B.2
Sikole, A.3
-
53
-
-
20544460709
-
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study
-
DOI 10.1681/ASN2004060512
-
Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16;800-7. DOI 10.1681/ASN2004060512
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 800-807
-
-
Lindberg, J.S.1
Culleton, B.2
Wong, G.3
-
54
-
-
11144353767
-
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
-
Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
-
(2004)
N Engl J Med
, vol.350
, pp. 1516-1525
-
-
Block, G.A.1
Martin, K.J.2
De Francisco, A.L.3
-
55
-
-
0042343804
-
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
-
Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
-
(2003)
N Engl J Med
, vol.349
, pp. 446-456
-
-
Teng, M.1
Wolf, M.2
Lowrie, E.3
Ofsthun, N.4
Lazarus, M.5
Thadhani, R.6
-
56
-
-
20844459261
-
Activated injectable vitamin D and hemodialysis survival: A historical cohort study
-
DOI 10-1681/ASN.2004070573
-
Teng M, Wolf M, Ofsthun N, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-25. DOI 10-1681/ASN.2004070573
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 1115-1125
-
-
Teng, M.1
Wolf, M.2
Ofsthun, N.3
-
57
-
-
20844433851
-
Which vitamin D derivative to prescribe for renal patients
-
Drueke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hyperten 2005;14:343-9.
-
(2005)
Curr Opin Nephrol Hyperten
, vol.14
, pp. 343-349
-
-
Drueke, T.B.1
-
58
-
-
20544454243
-
Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism
-
Gonzalez EA, Al-Aly Z, Martin KJ. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Semin Dial 2005;18:171-4.
-
(2005)
Semin Dial
, vol.18
, pp. 171-174
-
-
Gonzalez, E.A.1
Al-Aly, Z.2
Martin, K.J.3
-
59
-
-
23844456273
-
Beyond minerals and parathyroid hormone: Role of active vitamin D in end-stage renal disease
-
Wolf M, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial 2005;18:302-6.
-
(2005)
Semin Dial
, vol.18
, pp. 302-306
-
-
Wolf, M.1
Thadhani, R.2
-
60
-
-
23844437946
-
The role of vitamin D in vascular calcification in chronic kidney disease
-
Wolisi G, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005;18:307-14.
-
(2005)
Semin Dial
, vol.18
, pp. 307-314
-
-
Wolisi, G.1
Moe, S.M.2
-
61
-
-
33751002265
-
-
McKesson Corporation. San Francisco, California, (accessed 2006 May 19)
-
McKesson Corporation. San Francisco, California, http://supply.mckesson. com/portal/site/smoportal (accessed 2006 May 19).
-
-
-
|